Prognosis
Lilly Says Antibody Therapy May Lower Covid Hospitalizations
- Interim result sees 72% cut in hospitalizations with treatment
- Shares rise less than a percent as analysts seek more data
Photographer: David Paul Morris/Bloomberg
This article is for subscribers only.
Eli Lilly and Co.’s experimental antibody treatment for Covid-19 reduced the rate at which symptomatic patients were hospitalized compared to a placebo, according to preliminary study results released by the company and its partner.
Indianapolis-based Lilly and AbCellera Biologics Inc., a closely held Canadian biotechnology company, are co-developing neutralizing antibodies derived from one of the earliest patients in the U.S. to contract Covid-19. They are among a handful of companies, including Regeneron Pharmaceuticals Inc., AstraZeneca Plc., GlaxoSmithKline Plc and its partner Vir Biotechnology Inc. pursuing antibody therapies to combat the pandemic.